The Claim

Pharmacological inhibition of SIRT5 maintains mitochondrial energetic homeostasis in human HepG2 liver cells under lipotoxic conditions induced by excess free fatty acids, as evidenced by the normalization of ATP/ADP, NAD+/NADH, NADP+/NADPH ratios, and intracellular glutathione levels.

Source: SIRT5 rs12216101 T>G variant is associated with liver damage and mitochondrial dysfunction in patients with non-alcoholic fatty liver disease.

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
42score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

How it works
1 study reviewed
In plain English

Blocking a protein called SIRT5 helps liver cells keep their energy and internal balance healthy when they're overwhelmed with fat.

See the scientific wording

Pharmacological inhibition of SIRT5 preserves mitochondrial energetic homeostasis in human liver cells (HepG2) exposed to excess free fatty acids, as shown by restoration of ATP/ADP, NAD+/NADH, NADP+/NADPH ratios, and glutathione levels.

What the research says

1 study

  1. Study: SIRT5 rs12216101 T>G variant is associated with liver damage and mitochondrial dysfunction in patients with non-alcoholic fatty liver disease.

    The study tested a drug that turns off a protein called SIRT5 in liver cells with too much fat, and found it helped the cells' energy and defenses return to normal, just like the claim says.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.